Please login to the form below
trastuzumab emtansine
This page shows the latest trastuzumab emtansine news and features for those working in and with pharma, biotech and healthcare.
NICE relents on Kadcyla after Roche pricing negotiations
The agreement comes after years of wrangling between NICE and the pharma group over the price of Kadcyla (ado-trastuzumab emtansine), which has a list price of £90, 000 a year ... older HER2-targeting drug Herceptin (trastuzumab) with capecitabine that
Latest news
-
A new decade of disruption: meeting the biosimilar challgenge
High price tags have seen a string of rejections for routine NHS use by the UK watchdog NICE, including cancer MAbs Avastin (bevacizumab), Kadcyla (ado-trastuzumab emtansine) and Perjeta (pertuzumab). ... An example can be seen in Roche’s introduction
-
Roche in "unprecedented" launch period for new medicines
The star in Roche's show was once again its trio of HER2-positive breast cancer drugs - Herceptin (trastuzumab), Perjeta (pertuzumab) and Kadcyla (trastuzumab emtansine) - whose sales increased 9% to
-
Roche's melanoma combo "too expensive" for NHS use, says NICE
NICE arrived at a similar conclusion when it published a review of breast cancer drugs Perjeta (pertuzumab) in May and Kadcyla (trastuzumab-emtansine) at the end of last year.
-
Immunotherapy and future directions in oncology
Monoclonal antibody-based technologies have now been in use for decades targeting specific cancer cells to serve either as therapeutics (eg Genentech's trastuzumab, Herceptin) or invitro diagnostics (immunoassays) or to ... Kadcyla (trastuzumab emtansine,
-
Roche says Tecentriq "off to a good start"
Strong gains for Perjeta (pertuzumab) and Kadcyla (ado-trastuzumab emtansine) reinforced a 5% increase for HER2 stalwart Herceptin (trastuzumab) to 3.4bn francs.
More from news
Approximately 5 fully matching, plus 49 partially matching documents found.
Latest Intelligence
-
An eye towards the biobetter in South Korea
It was noteworthy that the Celltrion's announcement happened to coincide with Roche's clinical data presentation of its Herceptin biobetter, Trastuzumab-emtansine (T-DM1). ... CT-P26. Celltrion. Trastuzumab-dolastatin 10 antibody drug conjugate. S Korea.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
- Strategic Planner, Healthcare Advertising
-
£47, 000 – £53, 000
- Multi-Channel Account Managers - Road / Homebased – Full or Part...
-
Competitive salary
-
Client Services Director - Med Comms
-
Great salary and bebefits
- Home based, Editorial Team Leader, Medical Communications
-
Excellent package
- Home based, Senior Medical Writer, Medical Communications
-
Excellent package
- Account Director, Consumer Healthcare PR, Global PR agency
-
£50, 000 – £58, 000
- Home based, Principal Medical Writer, Medical Communications
-
Excellent package
- Account Director, Medical Communications
-
C£50 – 65, 000 benefits and bonus
- Senior Project Manager - Medical Writing
-
Great salary and bebefits
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
-
Senior Account Manager
-
Competitive salary commensurate with experience
- Business Unit Head, Medical Communications, London
-
Excellent package
-
Account Manager
-
£40, 000 - £45, 000 benefits
-
Healthcare PR Director
-
£100, 000 – £120, 000 benefits
- Head of Market Access - International - Based Cambridge
-
Excellent Basic, Bonus and Flex Benefits
- Home based, Chief Medical Writer, Medical Communications
-
Excellent package
Subscribe to our email news alerts
- Communiqué Awards 2018: Photo Gallery - Communiqué Awards 2016
- GSK sells eczema and psoriasis drug to Dermavant for £250m
- NHS England says yes to Roche's Hemlibra
- Moving annual total (MAT)
- Roche keeps Venclexta train rolling with new leukaemia filing
- Communiqué Awards 2018: Winners in pictures - Communiqué Awards 2016
- J&J’s Invokana aces diabetic kidney disease trial, setting up filings
- Research Partnership launches new patient Living with Diabetes (LATAM) 2018 report
- Scratching the surface: unmet needs in psoriasis
- Healthcare Comms news
- Shift to preventative healthcare - Opportunities for screening, diagnostics and vaccination
- Conference Live for ongoing congress performance measurement
PMHub
Quintiles Medical Communications
Quintiles’ award-winning medical communications group sits at the heart of the enterprise. We offer a range of innovative strategic services,...
Latest intelligence
- GDPR and events. What does the pharma industry need to know?
- ...
- Digital trends in B2B sales - how far behind is Pharma?
- The modern approach to B2B sales is data-driven, and enabled by digital tools....
- The rise of vertical integration in the US payer landscape
- Is it a solution to addressing the challenges of the value-based marketplace?...
Quick links
Infographics
